Adocia SA (EPA:ADOC)

France flag France · Delayed Price · Currency is EUR
4.736
+0.016 (0.34%)
Apr 24, 2026, 1:52 PM CET
Market Cap92.48M +50.5%
Revenue (ttm)3.85M -68.3%
Net Income-16.59M
EPSn/a
Shares Out19.59M
PE Ration/a
Forward PE7.95
Dividendn/a
Ex-Dividend Daten/a
Volume146,528
Average Volume285,477
Open4.728
Previous Close4.720
Day's Range4.638 - 4.830
52-Week Range3.300 - 12.400
Beta0.25
RSI45.29
Earnings DateApr 21, 2026

About Adocia

Adocia SA, a clinical-stage biotechnology company, researches and develops therapeutic solutions for diabetes and obesity. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company provides BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid prandial insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; and BioChaperone LisPram, a combination of pramlintide and lispro, as well as M1Pram, a combinati... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2005
Employees 77
Stock Exchange Euronext Paris
Ticker Symbol ADOC
Full Company Profile

Financial Performance

In 2025, Adocia's revenue was 3.85 million, a decrease of -68.26% compared to the previous year's 12.12 million. Losses were -16.59 million, 78.0% more than in 2024.

Financial Statements